Cardiff Oncology/CRDF

$3.24

1.25%
-
1D1W1MYTD1YMAX

About Cardiff Oncology

Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.

Ticker

CRDF

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mark Erlander

Employees

31

Headquarters

San diego, United States

Cardiff Oncology Metrics

BasicAdvanced
$145M
Market cap
-
P/E ratio
-$0.90
EPS
1.87
Beta
-
Dividend rate
$145M
1.87179
$6.42
$0.94
2M
5.91
-44.55%
-51.15%
-50.1%
238.287
2.386
2.387
54.43%
-1.69%
10.07%

What the Analysts think about Cardiff Oncology

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 2 analysts.
224.07% upside
High $14.00
Low $7.00
$3.24
Current price
$10.50
Average price target

Cardiff Oncology Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-5,000% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$200K
100%
Net income
-$10M
7.53%
Profit margin
-5,000%
-46.24%

Cardiff Oncology Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 11.11%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.25
-$0.22
-$0.21
-$0.22
-
Expected
-$0.26
-$0.29
-$0.28
-$0.25
-$0.25
Surprise
-3.55%
-22.81%
-24.32%
-11.11%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Cardiff Oncology stock?

Cardiff Oncology (CRDF) has a market cap of $145M as of May 30, 2024.

What is the P/E ratio for Cardiff Oncology stock?

The price to earnings (P/E) ratio for Cardiff Oncology (CRDF) stock is 0 as of May 30, 2024.

Does Cardiff Oncology stock pay dividends?

No, Cardiff Oncology (CRDF) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next Cardiff Oncology dividend payment date?

Cardiff Oncology (CRDF) stock does not pay dividends to its shareholders.

What is the beta indicator for Cardiff Oncology?

Cardiff Oncology (CRDF) has a beta rating of 1.87. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Cardiff Oncology stock price target?

The target price for Cardiff Oncology (CRDF) stock is $10.5, which is 223.08% above the current price of $3.25. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Cardiff Oncology stock

Buy or sell Cardiff Oncology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing